Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Barrett

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Expert Opinion on Therapeutic Targets|December 9, 2004
MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistanceJohn F Barrett
Expert Opinion on Drug Safety|December 24, 2005
Potential risk of probiotic usageJohn F Barrett
Current Opinion in Investigational Drugs (London, England : 2000)|August 27, 2005
Recent developments in glycopeptide antibacterialsJohn F Barrett
Current Opinion in Microbiology|August 30, 2005
Can biotech deliver new antibiotics?John F Barrett
Expert Opinion on Therapeutic Targets|June 7, 2005
MRSA--what is it, and how do we deal with the problem?John F Barrett
Expert Opinion on Therapeutic Targets|January 24, 2003
Targeting DNA gyraseJohn F Barrett
Idrugs : the Investigational Drugs Journal|August 9, 2003
American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USAJohn F Barrett
Current Protocols in Pharmacology|September 29, 2011
Overview of anti-infective drug developmentJohn F Barrett
Expert Opinion on Investigational Drugs|January 26, 2006
What are we looking for in new antibacterials and how do we design it?John F Barrett, Mary Motyl
Idrugs : the Investigational Drugs Journal|May 6, 2004
Patent alertPeter Norman, John F Barrett
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Expert Opinion on Therapeutic Targets|December 9, 2004
MRSA: status and prospects for therapy? An evaluation of key papers on the topic of MRSA and antibiotic resistanceJohn F Barrett
Expert Opinion on Drug Safety|December 24, 2005
Potential risk of probiotic usageJohn F Barrett
Current Opinion in Investigational Drugs (London, England : 2000)|August 27, 2005
Recent developments in glycopeptide antibacterialsJohn F Barrett
Current Opinion in Microbiology|August 30, 2005
Can biotech deliver new antibiotics?John F Barrett
Expert Opinion on Therapeutic Targets|June 7, 2005
MRSA--what is it, and how do we deal with the problem?John F Barrett
Expert Opinion on Therapeutic Targets|January 24, 2003
Targeting DNA gyraseJohn F Barrett
Idrugs : the Investigational Drugs Journal|August 9, 2003
American Society for Microbiology-103rd General Meeting. 18-22 May 2003, Washington DC, USAJohn F Barrett
Current Protocols in Pharmacology|September 29, 2011
Overview of anti-infective drug developmentJohn F Barrett
Expert Opinion on Investigational Drugs|January 26, 2006
What are we looking for in new antibacterials and how do we design it?John F Barrett, Mary Motyl
Idrugs : the Investigational Drugs Journal|May 6, 2004
Patent alertPeter Norman, John F Barrett
Pageof 4